These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 25453521

  • 1. Effect of gefitinib plus Chinese herbal medicine (CHM) in patients with advanced non-small-cell lung cancer: a retrospective case-control study.
    Yang XB, Wu WY, Long SQ, Deng H, Pan ZQ.
    Complement Ther Med; 2014 Dec; 22(6):1010-8. PubMed ID: 25453521
    [Abstract] [Full Text] [Related]

  • 2. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
    Yang XB, Wu WY, Long SQ, Deng H, Pan ZQ, He WF, Zhou YS, Liao GY, Li QP, Xiao SJ, Cai JZ.
    Trials; 2015 Apr 10; 16():146. PubMed ID: 25873045
    [Abstract] [Full Text] [Related]

  • 3. Gefitinib plus Fuzheng Kang'ai Formula () in Patients with Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation: A Randomized Controlled Trial.
    Yang XB, Chai XS, Wu WY, Long SQ, Deng H, Pan ZQ, He WF, Zhou YS, Liao GY, Xiao SJ.
    Chin J Integr Med; 2018 Oct 10; 24(10):734-740. PubMed ID: 28795387
    [Abstract] [Full Text] [Related]

  • 4. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ, Kmak KL, Koopmeiners J, Keshtgarpour M.
    Lung Cancer; 2006 Jan 10; 51(1):89-96. PubMed ID: 16290256
    [Abstract] [Full Text] [Related]

  • 5. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
    Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, Nagase S, Okamoto I, Yamanaka T, Tajima K, Harada R, Fukuoka M, Yamamoto N.
    Lancet Oncol; 2014 Oct 10; 15(11):1236-44. PubMed ID: 25175099
    [Abstract] [Full Text] [Related]

  • 6. A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer.
    Han JY, Lee SH, Yoo NJ, Hyung LS, Moon YJ, Yun T, Kim HT, Lee JS.
    Clin Cancer Res; 2011 Mar 15; 17(6):1553-60. PubMed ID: 21411446
    [Abstract] [Full Text] [Related]

  • 7. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03).
    Gaafar RM, Surmont VF, Scagliotti GV, Van Klaveren RJ, Papamichael D, Welch JJ, Hasan B, Torri V, van Meerbeeck JP, EORTC Lung Cancer Group and the Italian Lung Cancer Project.
    Eur J Cancer; 2011 Oct 15; 47(15):2331-40. PubMed ID: 21802939
    [Abstract] [Full Text] [Related]

  • 8. Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.
    Kim ST, Lee J, Kim JH, Won YW, Sun JM, Yun J, Park YH, Ahn JS, Park K, Ahn MJ.
    Cancer; 2010 Jun 15; 116(12):3025-33. PubMed ID: 20564408
    [Abstract] [Full Text] [Related]

  • 9. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
    Spigel DR, Burris HA, Greco FA, Shipley DL, Friedman EK, Waterhouse DM, Whorf RC, Mitchell RB, Daniel DB, Zangmeister J, Bass JD, Hainsworth JD.
    J Clin Oncol; 2011 Jun 20; 29(18):2582-9. PubMed ID: 21576636
    [Abstract] [Full Text] [Related]

  • 10. Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group.
    Agarwala A, Fisher W, Bruetman D, McClean J, Taber D, Titzer M, Juliar B, Yu M, Breen T, Einhorn LH, Hanna N.
    J Thorac Oncol; 2008 Apr 20; 3(4):374-9. PubMed ID: 18379355
    [Abstract] [Full Text] [Related]

  • 11. Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study.
    Wu YL, Fukuoka M, Mok TS, Saijo N, Thongprasert S, Yang JC, Chu DT, Yang JJ, Rukazenkov Y.
    Lung Cancer; 2013 Aug 20; 81(2):280-7. PubMed ID: 23540718
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation.
    Igawa S, Kasajima M, Ishihara M, Kimura M, Hiyoshi Y, Niwa H, Kusuhara S, Harada S, Asakuma M, Otani S, Katono K, Sasaki J, Masuda N.
    Cancer Chemother Pharmacol; 2014 Nov 20; 74(5):939-46. PubMed ID: 25173459
    [Abstract] [Full Text] [Related]

  • 13. Chinese herbal medicine as maintenance therapy for improving the quality of life for advanced non-small cell lung cancer patients.
    Han Y, Wang H, Xu W, Cao B, Han L, Jia L, Xu Y, Zhang Q, Wang X, Zhang G, Yu M, Yang G.
    Complement Ther Med; 2016 Feb 20; 24():81-9. PubMed ID: 26860807
    [Abstract] [Full Text] [Related]

  • 14. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial.
    Zhang L, Ma S, Song X, Han B, Cheng Y, Huang C, Yang S, Liu X, Liu Y, Lu S, Wang J, Zhang S, Zhou C, Zhang X, Hayashi N, Wang M, INFORM investigators.
    Lancet Oncol; 2012 May 20; 13(5):466-75. PubMed ID: 22512843
    [Abstract] [Full Text] [Related]

  • 15. Clinicopathologic factors affecting the progression-free survival of patients with advanced non-small-cell lung cancer after gefitinib therapy.
    Masago K, Fujita S, Togashi Y, Kim YH, Hatachi Y, Fukuhara A, Nagai H, Sakamori Y, Mio T, Mishima M.
    Clin Lung Cancer; 2011 Jan 20; 12(1):56-61. PubMed ID: 21273181
    [Abstract] [Full Text] [Related]

  • 16. Effect of gefitinib challenge to initial treatment with non-small cell lung cancer.
    Chen X, Li W, Hu X, Geng Y, Wang R, Yin Y, Shu Y.
    Biomed Pharmacother; 2011 Dec 20; 65(8):542-6. PubMed ID: 21840160
    [Abstract] [Full Text] [Related]

  • 17. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C.
    Lancet Oncol; 2012 Mar 20; 13(3):247-55. PubMed ID: 22341744
    [Abstract] [Full Text] [Related]

  • 18. [Prognostic analysis of stage III-IV non-small cell lung cancer patients treated by traditional chinese medicine].
    Zhou DH, Lin LZ, Zhou YQ, Luo RC, Liu KF, Jia YJ, Chen JY, Niu XW, Su BR, Lu J, Wang ST.
    Ai Zheng; 2005 Oct 20; 24(10):1252-6. PubMed ID: 16219143
    [Abstract] [Full Text] [Related]

  • 19. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
    Brown T, Boland A, Bagust A, Oyee J, Hockenhull J, Dundar Y, Dickson R, Ramani VS, Proudlove C.
    Health Technol Assess; 2010 Oct 20; 14(Suppl. 2):71-9. PubMed ID: 21047494
    [Abstract] [Full Text] [Related]

  • 20. Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases.
    Song Z, Zhang Y.
    J Clin Neurosci; 2014 Apr 20; 21(4):591-5. PubMed ID: 24256883
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.